Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK
Abstract Sepsis capillary leak syndrome (SCLS) is an independent prognostic factor for poor sepsis outcome. We previously demonstrated that α1AMP-activated protein kinase (α1AMPK) prevents sepsis-induced vascular hyperpermeability by mechanisms involving VE-cadherin (VE-Cad) stabilization and activa...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dc9c7a02d37340ff943334e7a5f7da61 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:dc9c7a02d37340ff943334e7a5f7da61 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dc9c7a02d37340ff943334e7a5f7da612021-12-02T16:31:54ZCanagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK10.1038/s41598-021-93156-12045-2322https://doaj.org/article/dc9c7a02d37340ff943334e7a5f7da612021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93156-1https://doaj.org/toc/2045-2322Abstract Sepsis capillary leak syndrome (SCLS) is an independent prognostic factor for poor sepsis outcome. We previously demonstrated that α1AMP-activated protein kinase (α1AMPK) prevents sepsis-induced vascular hyperpermeability by mechanisms involving VE-cadherin (VE-Cad) stabilization and activation of p38 mitogen activated protein kinase/heat shock protein of 27 kDa (p38MAPK/HSP27) pathway. Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, has recently been proven to activate AMPK in endothelial cells. Therefore, we hypothesized that canagliflozin could be of therapeutic potential in patients suffering from SCLS. We herein report that canagliflozin, used at clinically relevant concentrations, counteracts lipopolysaccharide-induced vascular hyperpermeability and albumin leakage in wild-type, but not in endothelial-specific α1AMPK-knockout mice. In vitro, canagliflozin was demonstrated to activate α1AMPK/p38MAPK/HSP27 pathway and to preserve VE-Cad’s integrity in human endothelial cells exposed to human septic plasma. In conclusion, our data demonstrate that canagliflozin protects against SCLS via an α1AMPK-dependent pathway, and lead us to consider novel therapeutic perspectives for this drug in SCLS.Marine AngéJulien De PoortereAudrey GinionSylvain BattaultMélanie DechampsGiulio G. MuccioliMartin RoumainJohann MorelleSébastien DruartThomas MathivetLuc BertrandDiego Castanares-ZapateroSandrine HormanChristophe BeauloyeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Marine Angé Julien De Poortere Audrey Ginion Sylvain Battault Mélanie Dechamps Giulio G. Muccioli Martin Roumain Johann Morelle Sébastien Druart Thomas Mathivet Luc Bertrand Diego Castanares-Zapatero Sandrine Horman Christophe Beauloye Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK |
| description |
Abstract Sepsis capillary leak syndrome (SCLS) is an independent prognostic factor for poor sepsis outcome. We previously demonstrated that α1AMP-activated protein kinase (α1AMPK) prevents sepsis-induced vascular hyperpermeability by mechanisms involving VE-cadherin (VE-Cad) stabilization and activation of p38 mitogen activated protein kinase/heat shock protein of 27 kDa (p38MAPK/HSP27) pathway. Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, has recently been proven to activate AMPK in endothelial cells. Therefore, we hypothesized that canagliflozin could be of therapeutic potential in patients suffering from SCLS. We herein report that canagliflozin, used at clinically relevant concentrations, counteracts lipopolysaccharide-induced vascular hyperpermeability and albumin leakage in wild-type, but not in endothelial-specific α1AMPK-knockout mice. In vitro, canagliflozin was demonstrated to activate α1AMPK/p38MAPK/HSP27 pathway and to preserve VE-Cad’s integrity in human endothelial cells exposed to human septic plasma. In conclusion, our data demonstrate that canagliflozin protects against SCLS via an α1AMPK-dependent pathway, and lead us to consider novel therapeutic perspectives for this drug in SCLS. |
| format |
article |
| author |
Marine Angé Julien De Poortere Audrey Ginion Sylvain Battault Mélanie Dechamps Giulio G. Muccioli Martin Roumain Johann Morelle Sébastien Druart Thomas Mathivet Luc Bertrand Diego Castanares-Zapatero Sandrine Horman Christophe Beauloye |
| author_facet |
Marine Angé Julien De Poortere Audrey Ginion Sylvain Battault Mélanie Dechamps Giulio G. Muccioli Martin Roumain Johann Morelle Sébastien Druart Thomas Mathivet Luc Bertrand Diego Castanares-Zapatero Sandrine Horman Christophe Beauloye |
| author_sort |
Marine Angé |
| title |
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK |
| title_short |
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK |
| title_full |
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK |
| title_fullStr |
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK |
| title_full_unstemmed |
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK |
| title_sort |
canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1ampk |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/dc9c7a02d37340ff943334e7a5f7da61 |
| work_keys_str_mv |
AT marineange canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT juliendepoortere canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT audreyginion canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT sylvainbattault canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT melaniedechamps canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT giuliogmuccioli canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT martinroumain canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT johannmorelle canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT sebastiendruart canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT thomasmathivet canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT lucbertrand canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT diegocastanareszapatero canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT sandrinehorman canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk AT christophebeauloye canagliflozinprotectsagainstsepsiscapillaryleaksyndromebyactivatingendotheliala1ampk |
| _version_ |
1718383840821510144 |